S
Sibel Ascioglu
Researcher at Hacettepe University
Publications - 27
Citations - 3202
Sibel Ascioglu is an academic researcher from Hacettepe University. The author has contributed to research in topics: Randomized controlled trial & Tuberculin. The author has an hindex of 16, co-authored 27 publications receiving 3079 citations. Previous affiliations of Sibel Ascioglu include National Institutes of Health & European Organisation for Research and Treatment of Cancer.
Papers
More filters
Journal ArticleDOI
Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
Sibel Ascioglu,John H. Rex,B.E. de Pauw,John E. Bennett,J. Bille,F. Crokaert,David W. Denning,J.P. Donnelly,J. E. Edwards,Z. Erjavec,D. Fiere,O. Lortholary,Johan Maertens,Jacques F. Meis,Thomas F. Patterson,J. Ritter,D. Selleslag,Palak Shah,David A. Stevens,Thomas J. Walsh +19 more
TL;DR: A set of research-oriented definitions for the IFIs most often seen and studied in immunocompromised patients with cancer is proposed and three levels of probability are proposed: "proven," "probable," and "possible."
Journal ArticleDOI
Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia.
TL;DR: Identification of risk factors and predictors of a poor outcome in patients with cancer with BT candidemia may have important implications in early diagnosis and appropriate therapy of these patients.
Journal ArticleDOI
Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey.
TL;DR: Seroprevalence of infection was 10% in a sample from an outbreak region and increased with patient age, indicating that the Crimean-Congo hemorrhagic fever virus had been previously present in Turkey.
Journal ArticleDOI
Ribavirin for patients with Crimean–Congo haemorrhagic fever: a systematic review and meta-analysis
TL;DR: A real uncertainty exists over the benefit of ribavirin in the treatment of CCHF, which necessitates the urgent conduct of a randomized placebo-controlled trial.
Journal ArticleDOI
Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey.
Nazif Elaldi,Hurrem Bodur,Sibel Ascioglu,Sibel Ascioglu,Aysel Kocagul Celikbas,Zülal Özkurt,Haluk Vahaboglu,Hakan Leblebicioglu,Neziha Yilmaz,Aynur Engin,Mehmet Şencan,Kemalettin Aydin,Ilyas Dokmetas,Mustafa Aydın Çevik,Başak Dokuzoğuz,Mehmet A. Taşyaran,Recep Öztürk,Mehmet Bakir,Ramazan Uzun +18 more
TL;DR: Ribavirin and supportive care are the only available choices for treatment of CCHF patients, but to ascertain the efficacy of ribavirin, more laboratory and observational studies are necessary and ultimately, to elucidate these conflicting results and evaluate the efficacy undoubtedly, a multicenter randomised controlled trial will be needed.